- Home
- PAXS vs DNTH Comparison
PAXS vs DNTH Comparison
Compare PAXS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- DNTH
- Stock Information
- Founded
- PAXS 2021
- DNTH 2015
- Country
- PAXS United States
- DNTH United States
- Employees
- PAXS N/A
- DNTH N/A
- Industry
- PAXS Investment Managers
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- DNTH Health Care
- Exchange
- PAXS Nasdaq
- DNTH Nasdaq
- Market Cap
- PAXS 700.2M
- DNTH 651.8M
- IPO Year
- PAXS N/A
- DNTH N/A
- Fundamental
- Price
- PAXS $15.81
- DNTH $24.30
- Analyst Decision
- PAXS
- DNTH Strong Buy
- Analyst Count
- PAXS 0
- DNTH 8
- Target Price
- PAXS N/A
- DNTH $54.00
- AVG Volume (30 Days)
- PAXS 195.0K
- DNTH 362.9K
- Earning Date
- PAXS 01-01-0001
- DNTH 08-07-2025
- Dividend Yield
- PAXS 11.72%
- DNTH N/A
- EPS Growth
- PAXS N/A
- DNTH N/A
- EPS
- PAXS N/A
- DNTH N/A
- Revenue
- PAXS N/A
- DNTH $4,854,000.00
- Revenue This Year
- PAXS N/A
- DNTH N/A
- Revenue Next Year
- PAXS N/A
- DNTH N/A
- P/E Ratio
- PAXS N/A
- DNTH N/A
- Revenue Growth
- PAXS N/A
- DNTH 17.87
- 52 Week Low
- PAXS $12.57
- DNTH $13.37
- 52 Week High
- PAXS $15.93
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- PAXS 71.08
- DNTH 69.50
- Support Level
- PAXS $15.46
- DNTH $19.84
- Resistance Level
- PAXS $15.66
- DNTH $21.18
- Average True Range (ATR)
- PAXS 0.10
- DNTH 1.58
- MACD
- PAXS -0.01
- DNTH 0.39
- Stochastic Oscillator
- PAXS 99.14
- DNTH 89.88
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.